Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Letizia Procaccio

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
British Journal of Cancer|December 9, 2022
Second-line therapy in pancreatic ductal adenocarcinoma (PDAC) patients with germline BRCA1-2 pathogenic variants (gBRCA1-2pv)Giulia Orsi, Alessandro Cavaliere, Giampaolo Tortora, et al.
Cancer Medicine|January 25, 2025
Real-World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline BRCA1-2 Pathogenic VariantsMichele Milella, Giulia Orsi, Mariacristina di Marco, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.
Pageof 3